# Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

> **NCT02426684** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 17 (actual)

## Conditions studied

- Renal Disease

## Interventions

- **DRUG:** IdeS® (Imlifidase)

## Key facts

- **NCT ID:** NCT02426684
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-16
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426684, "Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02426684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*